Robin Kral
Corporate Officer/Principal bei REATA PHARMACEUTICALS, INC.
Profil
Robin Kral currently works at Reata Pharmaceuticals, Inc., as Vice President-Licensing & Intellectual Property from 2004.
Mr. Kral also formerly worked at The University of Texas Southwestern Medical Center, as Associate Director-Venture Development and NPS Pharmaceuticals, Inc., as Principal.
Mr. Kral received his undergraduate degree and graduate degree from Texas Tech University and Masters Business Admin degree from David Eccles School of Business.
Aktive Positionen von Robin Kral
| Unternehmen | Position | Beginn |
|---|---|---|
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2004 |
Ehemalige bekannte Positionen von Robin Kral
| Unternehmen | Position | Ende |
|---|---|---|
| The University of Texas Southwestern Medical Center | Corporate Officer/Principal | - |
| NPS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Robin Kral
| Texas Tech University | Graduate Degree |
| David Eccles School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
NPS Pharmaceuticals, Inc.
 NPS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NPS Pharmaceuticals, Inc. developed drugs for bone and mineral disorders. It also developed Natpara for the treatment of adult hypoparathyroidism. The company was founded by Hunter Jackson and Thomas N. Parks on October 22, 1986 and is headquartered in Bedminster, NJ. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
